ArticlePloS one2026
Advanced glycation end product accumulation was associated with renal function impairment in males in large health examination population.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The accumulation of advanced glycation end products (AGEs) is a risk factor for renal dysfunction. However, no investigation has been conducted on the association between AGEs and renal function in health screening participants. Therefore, this study aimed to examine the association between AGEs and kidney function in health screening participants who underwent health screening examination. Overall, 1,651 health screening examinees without a history of renal dysfunction diagnosis were recruited and AGE accumulation was measured by skin autofluorescence (SAF). The association between estimated glomerular filtration rate (eGFR) and AGEs was subsequently investigated in all examinees. The mean age was 56.6 ± 9.5 years; 812 (49.1%) were males, and the mean eGFR was 73.3 ± 13.4 mL/min. Multiple regression analysis identified that AGEs were significantly negatively associated with eGFR. This finding was also observed in examinees with normal eGFR (≧ 90 mL/min/1.73 m2, G1 stage according to the Japanese Society of Nephrology: N = 207). In conclusion, skin AGEs were significantly negatively associated with eGFR. To clarify whether AGEs contribute to renal dysfunction progression, additional research is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.